News
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Topline results from the TROPION-Lung01 phase 3 trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care chemotherapy, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy.
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's Biologics License Application (BLA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive.
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023.
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will be hosting one-on-one investor meetings at the SVB Securities Therapeutics Forum, taking place on July 11-12, 2023 in New York, NY.
Biosion, Inc. Appoints Furqan Ahmed, PharmD as Vice President and Head of Business Development
Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company, today announced the appointment of Furqan Ahmed, PharmD., as the Vice President and Head of Business Development. In this position, Furqan will be responsible for all aspects of the company's global business development efforts to maximize the value of Biosion's platforms and innovative pipeline.
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today provided updates on its diverse pipeline of infectious disease (ID) and central nervous system (CNS) disease candidates and announced a pivotal leadership transition that will further advance its strategic priorities.
Henlius Forecasts Profit in 1H 2023
Henlius (2696.HK) released a positive profit forecast. Based on the preliminary assessment of the unaudited comprehensive management accounts for the six months ended June 30, 2023, the company expects to turn into profits in the first half of 2023, achieving profitability for the first time in a six-month period.
Crystal Pharmatech Recognized as “Best Partner” by Allorion Therapeutics for Excellent Services
Crystal Pharmatech, a leading pharmaceutical technology company, has received dual recognition from its esteemed partner, Allorion Therapeutics (Boston, US / Guangzhou, China) who is an innovation-based biotech company aiming at developing novel drug molecules for the treatment of oncology and autoimmune diseases for its exceptional services to support an FIH study.
Kexing Biopharm Makes it into China’s Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years
Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized on June 27 as one of "China's Top 20 Biopharmaceutical Enterprises" (blood products, vaccines and insulin) for two consecutive years.
280 Bio receives IND approval from the FDA for YL-17231
280Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for the investigational drug YL-17231, a small molecule inhibitor of RAS signaling.
